Yu W.,Sun Yat Sen University |
Hu S.,Chinese PLA General Hospital |
Xie Z.-Y.,Beijing Haidian Hospital |
He Z.-J.,Sun Yat Sen University |
And 6 more authors.
Journal of Surgical Research | Year: 2015
Background: Recent findings showed advantages of a novel pyruvate-enriched oral rehydration solution (Pyr-ORS) in resuscitation of burns. This study focused on effects of Pyr- ORS on the visceral blood perfusion (VBP), gastrointestinal function, and survival rate, compared with the bicarbonate-based World Health Organization-guided oral rehydration solution (WHO-ORS), during intragastric rehydration of lethal hemorrhagic shock in rats. Methods: Sixty adult rats were subjected to 45% total blood volume loss and were randomly allocated to the following three groups (n = 20): group NR (no fluid resuscitation), group PORS (oral Pyr-ORS rehydration), and group BORS (oral WHO-ORS rehydration), respectively. Other 10 rats were served as group NH (the sham group). Enteral rehydration lasted for 4 h after hemorrhage. The mean arterial pressure (MAP), VBP, and plasma enzymes activities of heart, liver, and kidney, and intestinal fatty acid binding protein were measured. Liver, kidney, and ileum were harvested for the evaluation of activities of oxidative enzymes and intestinal barrier protein (ZO-1). Other 84 rats with identical procedures without sampling were observed for their 24-h survival rates. Results: Pyr-ORS wasmore effective in enhancing theMAP and VBP, inhibiting tissue oxidative damage, and improving organ function, compared with WHO-ORS. Hypoxic lactic acidosis was fully corrected in group PORS in 4 h, whereas it worsened in group BORS, and the 24-h survival rate was twice higher in group PORS than in group BORS (45.8 versus 20.8%, P < 0.05). Conclusions: A small amount of pyruvate in Pyr-ORS was more therapeutically beneficial than equivalent bicarbonate in WHO-ORS and greatly raised survival in enteral rehydration of lethal hemorrhagic shock. The Pyr-ORS may be an ideal oral fluid in resuscitation of hypovolemic shock, especially in prehospital and resource-poor settings. © 2015 Elsevier Inc. All rights reserved.
Wang L.-Y.,Beijing Center for Diseases Prevention and Control |
Sun M.-P.,Beijing Center for Diseases Prevention and Control |
Zhang X.-C.,Beijing Center for Diseases Prevention and Control |
Suo L.-D.,Beijing Center for Diseases Prevention and Control |
And 4 more authors.
Vaccine | Year: 2011
To provide basis for human rabies vaccination in China, the safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use were assessed. A total of 250 volunteers were enrolled and divided into two groups: volunteers in Group A (n=200) were vaccinated five doses of Speeda Vero cell rabies vaccine manufactured by Liaoning Chengda Biotechnology Co. Ltd. on day 0, 3, 7, 14, 28 after exposure. Volunteers in Group B (n=50) were treated with Verorab Vero cell rabies vaccine manufactured by Sanofi Pasteur on the same schedule. The local and systematic adverse reactions were observed. Serum neutralizing antibody levels of 80 individuals in Group A and 50 individuals in Group B were tested with RFFIT on day 7, 14, 45, 180, 360 after the first dose. The seroconversion rates in Groups A and B were 40.3% and 37.0% on day 7 after the first dose, 95.5% and 97.7% on day 14, 100% and 100% on day 45, 100% and 100% on day 180, 89.1% and 89.5% on day 360 respectively, indicating no significant differences between the two groups. And no significant differences were found between the neutralizing antibody geometric mean titers (GMTs) of the two groups on day 7, 14, 45, 180 and 360 after the first dose, with the GMTs of day 14, 45, 180 and 360 all higher than 0.5. IU/ml. Antibody levels of the two groups peaked around 2 weeks after the full vaccination program, followed by a 55% decrease up to day 180 and another 76% decrease up to day 360. Both groups experienced occasions of transient fever, rash, edema, and scleroma after vaccination. Neither group had any severe adverse reactions. It was concluded that both vaccines showed satisfactory safety and immunogenicity. Booster vaccination is recommended following another exposure after six months since the full vaccination program. © 2011 Elsevier Ltd.
Chen Y.-D.,Capital Medical University |
Li S.-J.,Capital Medical University |
Sun F.-H.,Beijing Haidian Hospital |
Liu Y.-Y.,General Hospital of CAAC |
Hu W.-L.,Capital Medical University
European Neurology | Year: 2011
Background/Aims: Post-stroke complications may influence prognosis, and may even become potentially life-threatening. The aim of this prospective study was to examine the frequency and timing of medical complications during the acute stage of critical ischemic stroke in patients treated in a neurological intensive care unit. Methods: Seventy acute ischemic stroke patients in a critical condition with morbid changes in organs other than the brain or with severe complications were admitted to a neurological intensive care unit and followed up with assessments of 15 specified complications during the first 2 weeks on days 2, 4, 7, and 14. Results: The most common complications within 2 weeks of onset were chest infection (90%), fever (64%), hypoalbuminemia (56%), arrhythmia (46%), irritable ulcer (44%), gastrointestinal dysfunction (39%), progression or recurrence of stroke (33%), and urinary tract infection (30%). The incidence of progression or recurrence of stroke and urinary tract infection peaked at day 2, and the incidence of arrhythmia, fever, chest infection, irritable ulcer, gastrointestinal dysfunction, and malnutrition peaked from 1 to 2 weeks. Conclusion: Progression or recurrence of stroke, fever, and chest infection are common complications in the acute stage of critical ischemic stroke. Copyright © 2011 S. Karger AG.
Meng L.,Peking University |
Wang J.,Peking University |
Ding W.-H.,Peking University |
Han P.,Beijing Haidian Hospital |
And 3 more authors.
Postgraduate Medical Journal | Year: 2013
Background The evaluation of ventricular remodelling and functional recovery is essential in predicting the prognosis of patients with acute myocardial infarction (AMI). Objective To determine the plasma catestatin level in patients with AMI, and investigate the association between plasma catestatin and heart function, and with left ventricular remodelling (LVR). Methods Fifty-eight consecutive patients who were admitted within 12 h of the onset of their ST-segment elevation myocardial infarction symptoms between 1 October 2009 and 30 June 2011 were prospectively recruited. Circulating catestatin was measured by ELISA. All patients underwent an echocardiography examination during the first week; 31 patients had a second echocardiography examination 3 months after the myocardial infarction. Results Plasma catestatin at the time of admission was significantly higher in patients than in normal controls. The level increased further in the first week after AMI. Three months after AMI, the plasma catestatin level of patients was comparable to that of normal controls. The plasma level of catestatin correlated with anterior AMI and left ventricular ejection fraction (LVEF) in the acute stage. Compared with patients without LVR, those with LVR had significantly higher level of plasma brain natriuretic peptide on day 7 and a significantly higher level of plasma catestatin on admission and on days 3 and 7 (p=0.033, p=0.001, p=0.006, p=0.021, respectively). Conclusions Plasma catestatin levels were raised after AMI. An early increase of catestatin correlated with anterior AMI and LVEF. Plasma catestatin after the onset of AMI might be associated with the magnitude of progressive ventricular remodelling 3 months after AMI.
Zhang G.,Beijing Haidian Hospital |
Liu Y.,Capital Medical University |
Yu L.,Beijing Haidian Hospital |
Sun L.,National Institute for Infectious Disease Control and Prevention
Oncology Reports | Year: 2012
Since mucosal high-risk human papillomavirus (HPV) E6 can target and degrade the tumor suppressor p53, it is recognized as a major causative agent of cervical cancer. However, to date the distribution of high-risk HPV-E6 protein remains elusive. Thus, in the present study we used a mammalian green fluorescent protein (GFP) expression system to express a GFP/HPV-16E6 fusion protein (GFP-16E6) in wildtype (wt) p53 cells, such as MCF-7 and 293T cells to investigate the trafficking and localization of E6 and p53. Following transfection, we observed that the overexpressed GFP-16E6 was a nuclear protein, and that endogenous wt p53 localized to the nucleus together with GFP-16E6. Strikingly, p53 levels were not decreased but increased in 24 h transfected with pGFP-16E6. Furthermore, we observed significant apoptosis induced by GFP-16E6, which proved to be dependent on p53 expression.